Aprameya Engineering Pivots to Product-Led Platform, Reports Normalized Collections After FY26 Challenges

Aprameya Engineering Pivots to Product-Led Platform, Reports Normalized Collections After FY26 Challenges​

Aprameya Engineering Limited, a specialized healthcare infrastructure company, provided a comprehensive update on its FY26 performance and strategic roadmap, detailing its move toward becoming a scalable healthcare infrastructure and product-led platform. The company, which offers turnkey solutions for medical infrastructure, ICUs, Operation Theatres, and medical gas pipeline systems, highlighted that its recent focus has been on normalizing collections, strengthening the balance sheet, and introducing structural growth engines.

The company acknowledged that FY26 saw a temporary impact on profitability and cash flows due to an unforeseen administrative transition and reshuffling across certain government departments, which caused delays in approvals, execution cycles, and receivable collections. Aprameya reported that a major portion of the pending receivables were recovered by the end of March 2026, with the remaining balance received in the first week of April 2026. Management stated that these delays were administrative in nature and did not diminish the underlying business opportunity.

Financial Performance and Stabilization​

The normalization of collections is reflected in the company’s balance sheet and cash flow statement.

Strategic Shift to Product-Led Model​

Aprameya Engineering is expanding beyond its traditional project-led model by entering into innovative product categories. The company has formed an exclusive partnership for robotic healthcare products, which is expected to boost its product portfolio and revenue in FY26-27.

In the advanced stages of discussions, the company is pursuing Exclusive Channel Distribution for MIS (Endo Vision). This initiative marks a significant transition from a purely project-led structure to a more diversified healthcare infrastructure and product-led platform, expected to help grow customer wallet share, improve margins, and establish repeatable revenue streams.

To broaden its medical technology footprint, the company established a 70%-owned subsidiary, Aprameya Medtech Private Limited, on October 4, 2025. This subsidiary's growth is supported by a ₹ 4.00 Cr corporate guarantee extended to Punjab National Bank.

De-risking and Growth Outlook​

The company has undertaken deliberate measures to reduce its dependency on any single geography or limited government ecosystem. By actively pursuing an expanded presence across multiple key geographies, Aprameya aims to lower concentration risk and build a more balanced, scalable, and resilient business model. Active engagement is currently underway with additional state governments, institutional healthcare buyers, and private hospital networks across India.

Looking ahead, Aprameya Engineering continues to participate in multiple bids and expects fresh order inflows from government and institutional healthcare projects. The management believes the next phase of growth will be underpinned by the ongoing healthcare infrastructure build-out in India, strong execution credentials, receivable normalization, and the entry into innovative healthcare products, including robotic solutions.

In terms of financial goals for FY 26-27, the company stated it has recovered approximately Rs 100 crores in total outstanding receivables to date and has already submitted bids on tenders amounting to approximately ₹ 190 Crores. Additionally, Aprameya Medtech Pvt. Ltd., the subsidiary, has commenced construction of a state-of-the-art manufacturing facility spanning approximately 45,000 sq. ft., expected to become operational by the end of CFY 26-27.

Saurabh Kishor Bhatt, Managing Director of Aprameya Engineering Limited, commented on the update, stating that the temporary working capital impact has been fully resolved, with collections normalized by the first week of April 2026. He noted, "Combined with our geographical de-risking efforts, we are confident of achieving scalable topline and bottom-line performance during CFY 2026-27."

APRAMEYA Stock Price Movement​

On Wednesday, shares of Aprameya Engineering Limited shed 7.66% to settle at ₹173, falling significantly from the previous day's close. Trading saw a volume of 68,000 shares, with the stock ranging between a day low of ₹169.15 and a high of ₹181.